Literature DB >> 23711752

Patient autonomy in multiple sclerosis--possible goals and assessment strategies.

C Heesen1, S Köpke, A Solari, F Geiger, J Kasper.   

Abstract

Patient autonomy has been increasingly acknowledged as prerequisite for successful medical decision making in Western countries. In medical decisions with a need to involve a health professional, patient autonomy becomes apparent in the extent of patients' participation in the communication as described in the concept of shared decision making. Patient autonomy can be derived from different perspectives or goals and the focus of evaluation approaches may vary accordingly. Multiple sclerosis (MS) is a paradigmatic disease to study patient autonomy mainly because MS patients are highly disease competent and due to ambiguous evidence on many aspects of disease-related medical decision making. This review gives an overview on measurement issues in studying decision making in MS, categorized according to prerequisites, process measures and outcomes of patient autonomy. As relevant prerequisites role preferences, risk attribution, risk tolerance, and risk knowledge are discussed. Regarding processes, we distinguish intra-psychic and interpersonal aspects. Intra-psychic processes are elucidated using the theory of planned behavior, which guided development of a 30-item scale to capture decisions about immunotherapy. Moreover, a theory of uncertainty management has been created resulting in the development of a corresponding measurement concept. Interpersonal processes evolving between physician and patient can be thoroughly analyzed from different perspectives by use of the newly developed comprehensive MAPPIN'SDM inventory. Concerning outcomes, besides health related outcomes, we discuss match of preferred roles during the decision encounters (preference match), decisional conflict as well as an application of the multidimensional measure of informed choice to decisions of MS patients. These approaches provide an overview on patient-inherent and interpersonal factors and processes modulating medical decision making and health behavior in MS and beyond.
Copyright © 2013. Published by Elsevier B.V.

Entities:  

Keywords:  Complex interventions; Immunotherapy decision making; Multiple sclerosis; Patient autonomy; Risk communication; Shared decision making

Mesh:

Year:  2013        PMID: 23711752     DOI: 10.1016/j.jns.2013.02.018

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  20 in total

1.  Assessing subjective quality of life domains after multiple sclerosis diagnosis disclosure.

Authors:  Katia Mattarozzi; Federica Casini; Elisa Baldin; Martina Baldini; Alessandra Lugaresi; Paola Milani; Erika Pietrolongo; Alberto Gajofatto; Maurizio Leone; Trond Riise; Luca Vignatelli; Roberto D'Alessandro
Journal:  Health Expect       Date:  2015-04-24       Impact factor: 3.377

2.  Disability may influence patient willingness to participate in decision making on first-line therapy in multiple sclerosis.

Authors:  Emanuele D'Amico; Carmela Leone; Francesco Patti
Journal:  Funct Neurol       Date:  2016 Jan-Mar

3.  A pilot study to improve adherence among MS patients who discontinue treatment against medical advice.

Authors:  Jared Bruce; Amanda Bruce; Sharon Lynch; Lauren Strober; Sean O'Bryan; Deborah Sobotka; Joan Thelen; Abigail Ness; Morgan Glusman; Kathy Goggin; Andrea Bradley-Ewing; Delwyn Catley
Journal:  J Behav Med       Date:  2015-11-12

4.  Probability discounting of treatment decisions in multiple sclerosis: associations with disease knowledge, neuropsychiatric status, and adherence.

Authors:  Jared M Bruce; Amanda S Bruce; Sharon Lynch; Joanie Thelen; Seung-Lark Lim; Julia Smith; Delwyn Catley; Derek D Reed; David P Jarmolowicz
Journal:  Psychopharmacology (Berl)       Date:  2018-09-22       Impact factor: 4.530

5.  aHSCT is superior to alemtuzumab in maintaining NEDA and improving cognition in multiple sclerosis.

Authors:  Vivien Häußler; Friederike Ufer; Jana Pöttgen; Christine Wolschke; Manuel A Friese; Nicolaus Kröger; Christoph Heesen; Jan-Patrick Stellmann
Journal:  Ann Clin Transl Neurol       Date:  2021-05-05       Impact factor: 4.511

6.  Magnetic resonance imaging in multiple sclerosis--patients' experiences, information interests and responses to an education programme.

Authors:  Judith Brand; Sascha Köpke; Jürgen Kasper; Anne Rahn; Imke Backhus; Jana Poettgen; Jan-Patrick Stellmann; Susanne Siemonsen; Christoph Heesen
Journal:  PLoS One       Date:  2014-11-21       Impact factor: 3.240

7.  An informed shared decision making programme on the prevention of myocardial infarction for patients with type 2 diabetes in primary care: protocol of a cluster randomised, controlled trial.

Authors:  Susanne Buhse; Ingrid Mühlhauser; Nadine Kuniss; Ulrich Alfons Müller; Thomas Lehmann; Katrin Liethmann; Matthias Lenz
Journal:  BMC Fam Pract       Date:  2015-03-31       Impact factor: 2.497

8.  Shared Decision Making and Autonomy Among US Participants with Multiple Sclerosis in the NARCOMS Registry.

Authors:  Stacey S Cofield; Nina Thomas; Tuula Tyry; Robert J Fox; Amber Salter
Journal:  Int J MS Care       Date:  2017 Nov-Dec

9.  The transition from first-line to second-line therapy in multiple sclerosis.

Authors:  Jan Dörr; Friedemann Paul
Journal:  Curr Treat Options Neurol       Date:  2015-06       Impact factor: 3.972

Review 10.  Spasticity in multiple sclerosis and role of glatiramer acetate treatment.

Authors:  Jose Eustasio Meca-Lallana; Rocío Hernández-Clares; Ester Carreón-Guarnizo
Journal:  Brain Behav       Date:  2015-07-14       Impact factor: 2.708

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.